1391054-02-6
1391054-02-6 結(jié)構(gòu)式
基本信息
4-氨基-5-己烯酸鹽酸鹽
VIGABATRIN(中間體)
Vigabatrin (Hydrochloride)
4-aminohex-5-enoic acid hydrochloride
4-Amino-5-hexenoic acid hydrochloride (1:1)
Γ-VINYL-GABA HYDROCHLORIDE
SABRIL HYDROCHLORIDE
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-B0033 | 4-氨基-5-己烯酸鹽酸鹽 Vigabatrin hydrochloride | 1391054-02-6 | 5 mg | 500元 |
| 2025/12/22 | HY-B0033 | 4-氨基-5-己烯酸鹽酸鹽 Vigabatrin hydrochloride | 1391054-02-6 | 10mg | 800元 |
| 2025/12/22 | HY-B0033 | 4-氨基-5-己烯酸鹽酸鹽 Vigabatrin hydrochloride | 1391054-02-6 | 50mg | 3200元 |
常見問題列表
A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin.
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models.